# Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

> **NCT04937959** · — · UNKNOWN · sponsor: **Novoic Limited** · enrollment: 40 (estimated)

## Conditions studied

- Alzheimer Disease
- Alzheimer's Disease (Incl Subtypes)
- Preclinical Alzheimer's Disease
- Prodromal Alzheimer's Disease
- Mild Cognitive Impairment
- Normal Cognition

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04937959
- **Lead sponsor:** Novoic Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-22
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937959, "Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04937959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*